CEFUZONAM SODIUM

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H14N7O5S4.Na
Molecular Weight	535.576
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[H][C@]12SCC(CSC3=CN=NS3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C4=CSC(N)=N4)C([O-])=O

InChI

InChIKey=BCMSQWPLFBUUKW-IXLPVNPSSA-M

InChI=1S/C16H15N7O5S4.Na/c1-28-21-9(7-5-31-16(17)19-7)12(24)20-10-13(25)23-11(15(26)27)6(4-30-14(10)23)3-29-8-2-18-22-32-8;/h2,5,10,14H,3-4H2,1H3,(H2,17,19)(H,20,24)(H,26,27);/q;+1/p-1/b21-9-;/t10-,14-;/m1./s1

HIDE SMILES / InChI

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/3613097
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/3322588

Cefuzoname (CZON, L-105) is a second-generation cephalosporin antibiotic, has broad spectrum on Gram-positive or -negative bacteria and may also be effective against Staphylococcus aureus against which third generation cephalosporins are largely ineffective.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Klebsiella pneumoniae growth 4 Target ID: Klebsiella pneumoniae growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/3613094	Inhibitor 8297
Escherichia coli growth 23 Target ID: Escherichia coli growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/3613094	Inhibitor 8297
Peptidoglycan biosynthesis 20 Target ID: map00550 Sources: http://www.kegg.jp/dbget-bin/www_bget?dr:D03432	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Chronic complicated urinary tract infection 2 Sources: http://www.ncbi.nlm.nih.gov/pubmed/3806950	Curative	Preclinical	Unknown Approved Use Unknown
Bronchopneumonia 4 Sources: http://www.ncbi.nlm.nih.gov/pubmed/3613086	Curative	Preclinical	Unknown Approved Use Unknown
Acute appendicitis 2 Sources: http://www.ncbi.nlm.nih.gov/pubmed/1960860	Curative	Preclinical	Unknown Approved Use Unknown
Lung abscess 2 Sources: http://www.ncbi.nlm.nih.gov/pubmed/2071958	Curative	Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
[Fundamental and clinical studies on cefuzoname in the pediatric field].	1987 Apr	3613094
Bone cement not weakened by cefuzonam powder.	1991 Jun	2042464
[Clinical studies on cefuzonam for acute peritonitis due to perforated appendicitis. Tissue concentration and clinical efficacy].	1991 Sep	1960860

Patents

Sample Use Guides

In Vivo Use Guide

Cefuzonam in a dose of 1 g was administered by intravenous bolus injection or intravenous drip infusion for 60 minutes.

Route of Administration: Intravenous

In Vitro Use Guide

The MIC80's of cefuzonam against Streptococcus pneumoniae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, Haemophilus influenzae and Citrobacter spp. were less than 0.20 ug/ml.

Name

Type

Language

CEFUZONAM SODIUM

Common Name

English

SODIUM CEFUZONAM

Common Name

English

5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-(((2Z)-2-(2-AMINO-4-THIAZOLYL)-2-(METHOXYIMINO)ACETYL)AMINO)-8-OXO-3-((1,2,3-THIADIAZOL-5-YLTHIO)METHYL)-, SODIUM SALT (1:1), (6R,7R)-

Common Name

English

Cefuzonam sodium [WHO-DD]

Common Name

English

CEFUZONAM SODIUM [JAN]

Common Name

English

5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-(((2-AMINO-4-THIAZOLYL)(METHOXYIMINO)ACETYL)AMINO)-8-OXO-3-((1,2,3-THIADIAZOL-5- YLTHIO)METHYL)-, SODIUM SALT, (6R-(6-ALPHA,7-BETA(Z)))-

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C357